Atara Biotherapeutics, Inc - ATRA STOCK NEWS

Atara Biotherapeutics (ATRA) reported Q3 2024 financial results and operational progress. The company's tab-cel® BLA is on track with a PDUFA date of January 15, 2025. Total revenues were $40.2 million, up from $2.1 million in Q3 2023. Net loss was $21.9 million ($2.93 per share). Cash position was $67.2 million as of September 30, 2024.

The company dosed its first patient in the ATA3219 Non-Hodgkin's Lymphoma study, with initial data expected Q1 2025. Atara expects to initiate studies for Lupus Nephritis and Extrarenal Systemic Lupus Erythematosus by year-end. The company projects its cash runway into 2027, supported by potential milestone payments and operational efficiencies.

Atara Biotherapeutics (Nasdaq: ATRA), a company specializing in T-cell immunotherapy and developing treatments for cancer and autoimmune diseases using its allogeneic Epstein-Barr virus (EBV) T-cell platform, has scheduled the release of its third quarter 2024 financial results. The results will be announced after market close on Tuesday, November 12, 2024.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, has reported the grant of 3,500 restricted stock units of its common stock to a newly hired employee. This award was approved by the Compensation Committee of Atara's Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of October 1, 2024.

The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date. The remainder vests in 12 approximately equal quarterly installments over the following three years, subject to continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement material to the new employee entering into employment with Atara.

Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, has granted 3,700 restricted stock units to a newly hired employee. This inducement grant, approved by the Compensation Committee and made under the company's 2018 Inducement Plan, is in accordance with Nasdaq Listing Rule 5635(c)(4). The grant date is September 3, 2024.

The restricted stock units have a four-year vesting schedule: 25% vests on the first quarterly vesting date after the first anniversary, with the remaining 75% vesting in 12 approximately equal quarterly installments over the following three years. Vesting is subject to continuous employment with Atara.

Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's Executive Vice President and Chief Scientific & Technical Officer, Cokey Nguyen, Ph.D., will present on Monday, September 9, 2024, at 6:30 a.m. PDT / 9:30 a.m. EDT.

Atara specializes in developing transformative therapies for patients with cancer and autoimmune diseases using its novel allogeneic Epstein-Barr virus (EBV) T-cell platform. Investors and interested parties can access a live webcast of the presentation through the Investors and Media section of atarabio.com. An archived replay will be available on the company's website for 30 days following the live presentation.

Atara Biotherapeutics (Nasdaq: ATRA) has announced a $36 million registered direct offering of common stock and pre-funded warrants. The offering, priced at $8.25 per share, represents a 15% premium to Atara's 7-day volume-weighted average price. Participants include existing top institutional investors and a new strategic investor from a large public biotechnology company. The proceeds will extend Atara's cash runway into 2027, supporting the U.S. BLA approval for tab-cel® and advancement of ATA3219. Greg Ciongoli, founder of Adiumentum Capital Management, will join Atara's Board of Directors. The offering is expected to close around September 5, 2024, subject to customary conditions.

Atara Biotherapeutics (Nasdaq: ATRA) reported Q2 2024 financial results and operational progress. Key highlights include:

1. Tab-cel® U.S. BLA accepted under Priority Review with PDUFA date of January 15, 2025.

2. ATA3219 studies in Lupus Nephritis and Severe Systemic Lupus Erythematosus to start Q4 2024; initial data expected mid-2025.

3. ATA3219 Non-Hodgkin's Lymphoma study enrolling; initial data expected Q1 2025.

4. Leadership changes: Pascal Touchon to become Chairman, Cokey Nguyen to be appointed President and CEO effective September 9, 2024.

5. Q2 2024 revenues: $28.6 million; net loss: $19.0 million ($3.10 per share).

6. Cash runway extended into 2027, enabling key pipeline readouts.

Atara Biotherapeutics (Nasdaq: ATRA), a leader in T-cell immunotherapy, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event is scheduled for August 14, 2024, at 8:30 a.m. PDT / 11:30 a.m. EDT.

Pascal Touchon, President and CEO, and Dr. Cokey Nguyen, Executive VP and Chief Scientific & Technical Officer, will represent the company. Atara specializes in developing transformative therapies for cancer and autoimmune diseases using its novel allogeneic Epstein-Barr virus (EBV) T-cell platform.

A live webcast of the presentation will be available on the Investors and Media section of atarabio.com, with an archived replay accessible for 30 days following the event.

Atara Biotherapeutics (Nasdaq: ATRA) announced that the U.S. FDA has accepted and granted Priority Review for the Biologics License Application (BLA) of tabelecleucel (tab-cel®) for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). The PDUFA target action date is set for January 15, 2025. If approved, tab-cel would be the first therapy in the U.S. for this indication.

The BLA acceptance triggers a $20 million milestone payment from Pierre Fabre Laboratories, with an additional $60 million milestone if approved by the FDA. The application is supported by data from over 430 patients, including the pivotal ALLELE study, which showed a statistically significant 48.8% Objective Response Rate. Tab-cel has already received marketing authorization in Europe, the UK, and Switzerland under the brand name Ebvallo™.